Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in asians and non-Asians with atrial fibrillation

Stroke

Volumn 44, Issue 7, 2013, Pages 1891-1896

  Hori, Masatsugu ^a   Connolly, Stuart J ^b   Zhu, Jun ^c   Liu, Li Sheng ^c   Lau, Chu Pak ^d   Pais, Prem ^e   Xavier, Denis ^e   Kim, Sung Soon ^f   Omar, Razali ^g   Dans, Antonio L ^h   Tan, Ru San ⁱ   Chen, Jyh Hong ^j   Tanomsup, Supachai ^k   Watanabe, Mitsunori ^l   Koyanagi, Masahide ^m   Ezekowitz, Michael D ⁿ   Reilly, Paul A ^o   Wallentin, Lars ^o   Yusuf, Salim ^b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c FUWAI HOSPITAL   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^f Yonsei University College of Medicine   (South Korea)

^g NATIONAL HEART INSTITUTE   (Malaysia)

^h PHILIPPINE GENERAL HOSPITAL   (Philippines)

ⁱ DEPARTMENT OF CARDIOLOGY   (Singapore)

^j NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^k MAHIDOL UNIVERSITY   (Thailand)

^l NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^m THOMAS JEFFERSON UNIVERSITY   (United States)

ⁿ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^o UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

Asia; atrial fibrillation; bleeding; dabigatran; intracranial hemorrhage; RE LY; warfarin

Indexed keywords

DABIGATRAN ETEXILATE; WARFARIN;

ADULT; AGED; ARTICLE; ASIAN; BLEEDING; BLOOD PRESSURE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DYSPEPSIA; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ASIA; ATRIAL FIBRILLATION; BLEEDING; DABIGATRAN; INTRACRANIAL HEMORRHAGE; RE-LY; WARFARIN;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BRAIN ISCHEMIA; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PYRIDINES; STROKE; WARFARIN;

EID: 84879962384     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.000990     Document Type: Article

References (15)

1. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007;50:309-315
2. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36: 1115-1119
3. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. Circ J. 2010;74:2479-2500
4. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: randomized evaluation of longterm anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805-810, 810.e2
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151
6. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-2372
7. Moyer TP, OKane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009;84:1079-1094
8. Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am J Med. Genet. 1997;73:334-336
9. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-Analysis. Lancet Neurol. 2010;9:167-176
10. Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL, Sorimachi T, et al.; Edinburgh Stroke Study Group. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke. 2010;41:1222-1228
11. Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology. 2006;66:165-171
12. Strazzullo P, DElia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-Analysis of prospective studies. BMJ. 2009;339:b4567.
13. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al.; RE-LY Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9:1157-1163
14. Nieuwlaat R, Connolly BJ, Hubers LM, Cuddy SM, Eikelboom JW, Yusuf S, et al.; ACTIVE Investigators. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Thromb Res. 2012;129:715-719
15. Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation-sub-Analysis in Japanese population in RE-LY trial. Circ J 2011;75:800-805.